The notion of obliterating the LAA grew out of the knowledge that most of the systemic emboli leading to stroke in patients with AF originate from the LAA. LAA exclusion was first attempted surgically ...
Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...
A novel study by Canadian physicians reported that the BioSTAR biodegradable implant achieved comparable closure rates to the Amplatzer Septal Occluder in children with atrial septal defect. A novel ...
ABBOTT PARK, Ill., Aug. 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the Amulet™ LAA Occluder IDE trial, a multi-center, head-to-head study comparing the company ...
At 2-year follow-up, a septal occluder device was deemed safe and effective for transcatheter closure of atrial septal defects, according to new data published in Circulation: Cardiovascular ...
It looks like a yo-yo, but it can stretch, flatten out, "swell up," or even "self-center," depending on what it needs to do to adjust itself to plug holes in the heart that make up some of the most ...
First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...
TCT 195: Percutaneous Patent Foramen Ovale Closure for Migraine with the Amplatzer PFO Occluder: A Pooled Analysis of Individual Participant Data from the Randomized Trials Receive the the latest news ...
A randomized trial has found low rates of procedural and long-term complications with three patent foramen ovale closure devices. Of note, a significantly lower rate of recurrent neurological events ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback